Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The company will engage in a fireside chat scheduled for 2:00 p.m. ET. The event will be webcast live and later archived for at least thirty days, accessible through Royalty Pharma's Events page.

Positive

• Participation in a high-profile event like the Goldman Sachs 45th Annual Global Healthcare Conference enhances Royalty Pharma's visibility within the healthcare sector.
• The archived webcast provides ongoing access for investors and stakeholders, promoting transparency and engagement.

Negative

• The press release lacks specific details on potential new developments or announcements to be made during the event.

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45^th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.   

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
ir@royaltypharma.com

FAQ

When is Royalty Pharma presenting at the Goldman Sachs 45th Annual Global Healthcare Conference?

Royalty Pharma is presenting on June 11, 2024, at 2:00 p.m. ET.

Where can I access the webcast for Royalty Pharma's presentation at the Goldman Sachs Healthcare Conference?

The webcast will be accessible from Royalty Pharma's Events page at https://www.royaltypharma.com/investors/events/.

What is the stock symbol for Royalty Pharma?

The stock symbol for Royalty Pharma is RPRX.

Will the webcast of Royalty Pharma's presentation at the Goldman Sachs Healthcare Conference be available for later viewing?

Yes, the webcast will be archived for at least thirty days.